Passage Bio Inc. reported a net loss of $7.7 million, or $2.44 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $19.3 million, or $6.15 per share, for the same period in 2024. Research and development expenses were $4.3 million, down from $8.7 million in the prior year quarter. General and administrative expenses were $4.3 million, compared to $7.3 million in the previous year. Cash, cash equivalents, and marketable securities totaled $52.8 million as of September 30, 2025, down from $84.8 million the year before. The company expects its cash resources to fund operations into the first quarter of 2027. Passage Bio is actively enrolling patients in its ongoing upliFT-D study and is on track to seek regulatory feedback on its FTD-GRN registrational trial design in the first half of 2026.